FDA Accepts Supplement Application for ERLEADA (Apalutamide)
The FDA has accepted a supplemental application for ERLEADA, a drug developed by Janssen Biotech.
Published: July 8, 2026
Updated: July 8, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Androgen Receptor Inhibitor
Asset: Janssen
Technology / Platform: androgen receptor inhibitors
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Janssen
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for ERLEADA is significant as it may lead to label expansions that enhance the drug's market position. This development underscores the importance of proactive portfolio management in response to regulatory changes.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent announcements regarding approval outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.